Scarica l'app Stockscreener
5.00
0.40%
0.02
Dopo l'orario di chiusura:
4.81
-0.19
-3.80%
Candel Therapeutics Inc Borsa (CADL) Ultime notizie
Candel Therapeutics, Inc. (CADL) Stock Price, News, Quote & History - Yahoo! Finance Canada
Candel Therapeutics, Inc. (CADL) stock price, news, quote and history - Yahoo Finance UK
Candel Therapeutics Inc. (CADL) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Bitget
Candel Therapeutics announces inducement grants under Nasdaq Listing Rule 5635(c)(4) - MarketScreener
Candel Therapeutics (CADL) director granted 4,618 fully vested stock options - Stock Titan
Director at Candel Therapeutics (NASDAQ: CADL) gets 2,795 options - Stock Titan
Candel Therapeutics (CADL) director granted fully vested stock options in lieu of cash fees - Stock Titan
Candel gives five new hires options for 70,000 shares at $4.90 - Stock Titan
CADL Technical Analysis & Stock Price Forecast - Intellectia AI
Insider Purchases Worth US$3.00m See Losses As Candel Therapeutics Market Value Drops To US$352m - simplywall.st
Candel gains on additional mid-stage trial data for lead asset - MSN
Glioma Pipeline Expands as 180+ Pharma Companies Advance Several Novel Therapies, Finds DelveInsight | Aivita Biomedical, Denovo BioPharma, Medicenna Therapeutics, Eli Lilly, Candel Therapeutics - Barchart.com
Paul Manning holds 7.9% of Candel Therapeutics (NASDAQ: CADL) shares - Stock Titan
Buy Signal: Should I hold or sell Candel Therapeutics Inc nowQuarterly Investment Review & Safe Capital Investment Plans - baoquankhu1.vn
H.C. Wainwright reiterates Candel stock rating on lung cancer data By Investing.com - Investing.com Australia
Will Candel Therapeutics Inc outperform small cap indexesWall Street Watch & Weekly High Conviction Trade Ideas - baoquankhu1.vn
H.C. Wainwright reiterates Candel stock rating on lung cancer data - Investing.com
Candel Therapeutics prices $100M public offering at $5.45 per share - MSN
Candel Therapeutics, Inc. (NASDAQ:CADL) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Market movers: Uber, Getty Images, Candel Therapeutics... - Proactive Investors
Candel Therapeutics reports extended survival in Phase 2a lung cancer trial of CAN-2409 - Proactive financial news
Candel reports extended survival data for lung cancer therapy - Investing.com
Candel Therapeutics Inc extended survival tail observed in trial of aglatimagene besadenovec - marketscreener.com
Candel Therapeutics Reports Extended Survival Tail Observed in Trial of Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors - Bitget
Candel Therapeutics Inc Extended Survival Tail Observed In Trial Of Aglatimagene Besadenovec - TradingView
Candel Therapeutics Reports Extended Survival Tail Observed - GlobeNewswire
Candel Therapeutics Reports Extended Survival Tail Observed in Trial of Aglatimagene Besadenovec (Can-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors - MarketScreener
Aug Drivers: Is Candel Therapeutics Inc stock forming a triangle pattern2026 Snapshot & Weekly High Return Opportunities - baoquankhu1.vn
FY2030 Earnings Forecast for CADL Issued By HC Wainwright - marketbeat.com
Short Interest in Candel Therapeutics, Inc. (NASDAQ:CADL) Grows By 39.7% - MarketBeat
Analysts Have Conflicting Sentiments on These Healthcare Companies: Revvity (RVTY) and Candel Therapeutics (CADL) - The Globe and Mail
Portolan Capital Management LLC Trims Position in Candel Therapeutics, Inc. $CADL - MarketBeat
Restrictive RTW Purchase Agreement Covenants Threaten Candel Therapeutics’ Financial Flexibility and Increase Default Risk - The Globe and Mail
Responsive Playbooks and the CADL Inflection - Stock Traders Daily
Citigroup Cuts Candel Therapeutics (NASDAQ:CADL) Price Target to $22.00 - MarketBeat
Candel Therapeutics (NASDAQ:CADL) Earns "Buy" Rating from Canaccord Genuity Group - MarketBeat
H.C. Wainwright reiterates Candel Therapeutics stock rating at buy By Investing.com - Investing.com India
H.C. Wainwright reiterates Candel Therapeutics stock rating at buy - Investing.com
Small cap wrap: 374Water, Ideal Power, Northstar Gold, Candel Therapeutics… - Proactive financial news
Candel Therapeutics (NASDAQ:CADL) Issues Quarterly Earnings Results, Misses Expectations By $0.30 EPS - MarketBeat
Candel Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Candel Therapeutics strengthens balance sheet as lead cancer therapy advances - Yahoo Finance
Candel Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights - Bitget
Candel Therapeutics, Inc. announces financial results for the fourth quarter and full year of fiscal 2025, along with recent strategic updates. - Bitget
CADL: Pivotal trials and BLA submission planned for 2026, with strong financial runway into 2028 - TradingView
BRIEF-Candel Therapeutics Q4 Net Income USD -29.496 Million - TradingView
Funding extends Candel Therapeutics (NASDAQ: CADL) cash runway into early 2028 - Stock Titan
Tech Rally: Is Candel Therapeutics Inc stock suitable for long term investing2026 Momentum Check & Real-Time Stock Price Movement Reports - baoquankhu1.vn
Candel Therapeutics (NASDAQ:CADL) Raised to Hold at Zacks Research - MarketBeat
Candel Therapeutics to present Phase 3 prostate cancer data at AUA 2026 - Proactive financial news
Candel Therapeutics Presents New Data From Phase 3 Trial Of Aglatimagene Besadenovec In Localized Prostate Cancer - marketscreener.com
Candel Therapeutics Back On The Radar As Prostate And Lung Cancer Trial Catalysts Approach - RTTNews
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):